11N 2 6 7006 B		
[\ \ . \ . \ . \ . \ . \ . \ . \ . \ .	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870,70000US00
FORM PTO- 199/A and B (the diffed PTO/SB/08) INFORMATION DISCLOSURE	FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753
STATEMENT BY APPLICANT	APPLICANT: Collins et al.	
Sheet 1 of 1	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication or Issue of Cited Document MM-DD-YYYY	
Initials #	No.	Number	Kind Code	Document		
1/#	A15	2002-0006432	A1	Collins et al.	01-17-2002	
VA	A16	2003-0170217	Al	Collins et al.	09-11-2003	
A	A17	2003-0215467	Al	Collins et al.	11-20-2003	
• ,						

FOREIGN PATENT DOCUMENTS

	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
	No.	Office/ Country	Number	Kind Code	Document	Cited Document MM-DD-YYYY	(Y/N)
•							
•							
					· · · · · · · · · · · · · · · · · · ·	1	<u> </u>

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
VA	.C152	Yildirim et al., "Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454," J Food Prot, 61(1):47-51, (1998). Abstract Only.	-

EXAMINER: V. Spenora	DATE CONSIDERED: 8-10-2006
----------------------	----------------------------

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

tilled on 6/12/2006

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00	
INFORMATION DISCLOSURE	FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753	
STATEMENT BY APPLICANT	APPLICANT: Collins et al.		
	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova	
Sheet 1 of 10	GROOF ART CIVIT. 1031	DAMMINER. YOU AILCHIOVA	

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Doo	cument	Name of Patentee or Applicant of Cited	Date of Publication or Issue	
Initials # No.		Number Kind Code		Document	of Cited Document MM-DD-YYYY	
14	Al	4,347,240		Mutai et al.	08-31-1982	
W.	A2	4,435,389		Mutai et al.	03-06-1984	
	A3	5,032,399		Gorbach et al.	07-16-1991	
	A4	5,443,826		Borody	08-22-1995	
	A5	5,711,977		Yang et al.	01-27-1998	
	A6	5,834,423		Koketsu et al.	11-10-1998	
	A7	5,922,375		Luchansky et al.	07-13-1999	
	A8	6,025,008		Akahoshi et al.	02-15-2000	
	A9	6,077,504		Cavaliere ved. Vesley et al.	06-20-2000	
	A10	6,132,710		Panigraphi et al.	10-17-2000	
	A11	6,368,591		Chen et al.	04-09-2002	
	A12	6,645,530		Borody	11-11-2003	
V	A13	2005-0214272	Al	Collins et al.	09-29-2005	
VA	A14	2006-0002908	A1	Collins et al.	01-05-2006	
				,		

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	For	eign Patent Docu	ıment	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)
VII	B1	EP	0 384 319	B1 _	VISKASE CORPORATION	04-28-1999	
1	B2	EP	0 508 701	Bl	QUEST INTERNATIONAL B.V.	07-10-1996	
	B3	EP	0 904 784	Al	N.V. NUTRICIA	03-31-1999	
	B4	EP	1 312 667	Al	WAKAMOTO PHARMACEUTICAL CO., LTD.	05-21-2003	
	B5	GB	1 503 094		NISSHIN FLOUR MILLING CO. LTD.	03-08-1978	·
	B6	JP .	9241173		WAKAMOTO PHARMACEUT CO.	09-16-1997	Y-Abstract
	B7	RU	2 091 075	C1	GNII GENETIKI I SELEKTSII PROM	09-27-1997	Y-Abstract
	B8	RU	2 109 054	C1	MOSKOVSKJJ	04-20-1998	Y-Abstract
1	B9	wo	89/05849	A1	CHR. HANSEN'S LABORATORIUM	06-29-1989	
VIY	B10	wo	90/01335	A1	THOMAS BORODY	02-22-1990	

EXAMINER: V. Hpremore	DATE CONSIDERED: $3-10-2006$
-----------------------	------------------------------

^{*} EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-	449/A and B (m	odified P	TO/SB/08)	APPLICATION NO.	10/783,020	ATTY. DOCKET NO.: A0870.70000US00	
	-		•	FILING DATE: Fel	oruary 23, 2004	CONFIRMATION NO.: 3753	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT:	Collins et al.		
				GROUP ART UNIT:	1651	EXAMINER: Vera Afremova	
Sheet	· 2	of	10	<u> </u>			

VH	B11	wo	90/09398	A1	BIOINVENT INTERNATIONAL AB	08-23-1990
M	B12	wo	97/35596	A1	ABBOTT LABORATORIES	10-02-1997
,	B13	wo	98/00035	Al	CAVALIERE VED. VESELY	01-08-1998
	B14	wo	98/35014	A2_	FORBAIRT TRADINGS AS BIORESEARCH IRELAND	08-13-1998
7	B15	wo	99/51631	Al	KORHONEN	10-14-1999
V	B16	wo	99/62348	A1	ENTERPRISE IRELAND	12-09-1999
VA	B17	wo	01/37865	A1	PROBIALL PTY LIMITED	05-31-2001
					·	<u> </u>

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
M	Cl	Adachi, Susumu, "Lactic Acid Bacteria and the Control of Tumours," The Lactic Acid Bacteria, 1:233-261, (1992).	
Á	C2	Anand et al., "Antibacterial Activity Associated with Bifidobacterium bifidum - II," Cult. Dairy Prod, pages 21-23, (1985). (Attached copy is missing 1 page)	
	C3	Arai et al., "Cytokines: Coordinators of Immune and Inflammatory Responses," Annual Rev. Biochem., 59:783-836, (1990).	
	C4	Aranda et al., "Analysis of Intestinal Lymphocytes in Mouse Colitis Mediated by Transfer of CD4 ⁺ , CD45RB ^{high} T Cells to SCID Recipients ¹ ," Jour. of Immunology, 158(7):3464-3473, (1997).	
	C5	Arihara, et al., "Salivacin 140, a novel bacteriocin from Lactobacillus salivarius subsp. salicinius T140 active against pathogenic bacteria," Letters in Applied Microbiology, 22:420-424, (1996).	
	C6	Bachwich, et al., "Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E ₂ Production in Resting Macrophages," Biochemical and Biophysical Res. Comm., 136(1):94-101, (1986).	
	C7	Blum et al., "Adhesion studies for probiotics: need for validation and refinement," Trends in Food Science & Technology, 10:405-410 (1999).	
	C8	Bouhnik et al., "Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans," Eur. Jour. Clin. Nut., 50:269-273, (1996).	
	C9	Bouhnik et al., "Survie et effets chez I'homme des bactéries ingérées dans less laits fermentés," LAIT, 73:241-247, (1993).	Y-Abstract
	C10	Brandtzaeg et al., "Immunopathology of human inflammatory bowel disease," Springer Semin Immunopath, 18:555-589, (1997).	
	C11	Brink et al., "Antimicrobial activity of lactobacilli: preliminary characteristization and optimization of production of acidocin B a novel bacteriocin produced by Lactobacillus acidophilus M," Jour. of Applied Bacteriology, 77:140-148, (1994).	
M	C12	Brzuszczak et al., "Cyclic AMP-dependent anion secretion in human small and large intestine," Jour. of Gastroenterology and Hepatology, 11:804-810, (1996).	

EXAMINER: V. Spenile	DATE CONSIDERED: 8-10-2006
, , , , , , , , , , , , , , , , , , ,	

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODM DTO)-1449/A and B (n	nodified	PT()/SD/08)	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753
	EMENT BY			APPLICANT: Collins et al.	
		-11-11		GROUP ART UNIT: 1651	EXAMINER: Vera Afremova
Sheet	3	of	10	GROOF ART UNIT: 1031	EAAWINER. VOI AITOMOVA

VY	7	C13	Charteris et al., "Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract," Letters in Applied Microbiology, 26:333-337, (1998).	
		C14	Charteris et al., "Selective detection, enumeration and identification of potentially probiotic Lactobacillus and Bifidobacterium species in mixed bacterial populations," Int. Jour. of Food Microbiology, 35:1-27, (1997).	
		C15	Charteris, et al., "Antibiotic Susceptibility of Potentially Probiotic Lactobacillus Species," Jour. Food Protection, 61(12):1636-1643, (1998).	
		C16	Charteris, et al., "Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract," Jour. of Applied Microbiology, 84:759-768, (1998).	
		C17	Chauvière et al., "Adhesion of human Lactobacillus acidophilus strain LB to human eterocyte-like Caco-2 cells," Journal of General Microbiology, 138:1689-1696, (1992).	
		C18	Chevalier et al., "Detection of Bifidobacterium species by enzymatic methods," Jour. of Appl. Bacteriology, 68:619-624, (1990).	
		C19	Cicco et al., "Inducible Production of Interleukin-6 by Human Polymorphonuclear Neutrophils: Role of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor-alpha," Blood, 75(10):2049-2052, (1990).	
		C20	Collins et al., "A Controlled Trial of Probiotic Treatment of IL-10 Knockout Mice," Gastroenterology, 116(4):1 page, (1999). Abstract G2981.	
		C21	Collins et al., "Demonstration of Probiotic Function in a Double Blind Placebo Controlled Clinical Trials in Adults," Functional Food Research in Europe, pages 40-41, (1998).	
		C22	Collins et al., "Probiotics and Man – The Host Microbe Interface," Gastroenterology, 116(4):1 page, (1999). Abstract G2982.	
		C23	Collins et al., "Selection of Probiotic Strains for Human Applications," Int. Dairy Journal, 8:487-490, (1998).	
		C24	Collins, "Probiotic Lactobacilli-Towards Defining Selection and Functional Criteria," Demonstration Fair CT96-1028, Page 27, (1996).	
		C25	Collins, "Selection of Probiotic Strains and Potential Therapeutic Applications," Book of Abstracts from Eur. Comm. Biotech and Fair Prog., page L-2, (1995).	
		C26	Collins et al., "Probiotic bacteria-interaction with the human immune system," Int. Congress and Symp. Series 219, pages 13-17, (1996).	
		C27	Collins, J.K., "Probiotics and Inflammatory Bowel Disease: Animal Models," Functional Food Research in Europe, page 124, (1998).	
		C28	Cong et al., "Genes, Bacteria, and T Cells: Ingredients for Inflammatory Bowel Disease," Gastroenterology, 115:1595-1596, (1998). (Summary by Shanahan, O'Sullivan, and Collins)	
		C29	Crabbe et al., "The Normal Microbial Flora as a Major Stimulus for Proliferation of Plasma Cells Synthesizing IgA in the Gut," Int. Arch. Allergy 34:362-375, (1968).	
		C30	Daly et al., "Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance," Antonie Van Leewenhoek, 70:99-110, (1996).	1
	Y	C31	Darveau, Richard, "Infection, inflammation, and cancer," Nature Biotechnology, 17:19, (1999).	

EXAMINER: DA	S-10-2006

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODM DTO	1.1449/A and B (m	odifie	1 PTO/SR/08\	APPLICATION NO.:	10/783,020	ATTY. DOCK	ET NO.: A0870.70000US00
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753	
				APPLICANT: (Collins et al.		
				GROUP ART UNIT:	1651	CVAMBIED.	Vera Afremova
Sheet	4	of	10	GROOP ART UNIT.		EXAMINER:	Vera Ariemova

VA	C32	Dawson et al., "18 pH, buffers, and physiological media," Data For Biochemical Research, pages 417-448, (1969).	
1	C33	Dekker et al., "Sensitive Pulsed Amperometric Detection of Free and Conjugated Bile Acids in Combination with Gradient Reversed-Phase HPLC," Chromatographia, 31(11/12):549-553, (1991).	
	C34	Dinarello et al., "New Concepts on the Pathogenesis of Fever," Reviews of Infectious Diseases, 10(1):168-189, (1988).	
	C35	Donnelly, et al., "Differential Regulation of IL-1 Production in Human Monocytes by IFN-γ and IL-4," Journal of Immunology, 145(2):569-575, (1990).	
	C36	Dunne et al., "Epithelial Adhesion of Probiotic Microorganisms in vitro and in vivo," Gastroenterology, 116(4):1 page, (1999). Abstract G3058.	
	C37	Dunne et al., "Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials," Antonie Van Leeuwenhoek, XP000929178, 76:279-292, (1999)/ Full - November, 1990)	· ·
	C38	Favier et al., "Fecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease," Digestive Diseases and Sci., 42(4):817-822, (1997).	
	C39	Feency et al., "Lack of Specific Systemic Immune Response on Oral Consumption of Probiotic Lactobacilli," Int. Dairy Journal, 8(5/6):1 page, (1998).	
	C40	Ferrante et al., "Effects of Tumour Necrosis Factor Alpha and Interleukin-1 Alpha and Beta on Human Neutrophil Migration, Respiratory Burst and Degranulation," Int. Archs Allergy Appl. Immun., 86:82-91, (1988).	
	C41	Flynn et al., "Isolation and Characterisation of the Novel Anitbacterial Proteins, ABP-1 and ABP-118 from Human Isolates Lactobacillus salivarius subsp. salivarius UCC-1 and UCC-118," Intl. Dairy Jour., 8(5/6):1 page, (1998).	
	C42	Fuller, "Probiotics in man and animals," Jour. of Applied Bacteriology, 66:365-378, (1989).	
	C43	Gahan et al., "Innate resistance to Listeria monocytogenes in tumor-bearing mice," Jour. of Leukocyte Biology, 62:726-732, (1997).	
	C44	Ganguly et al., "Mechanism of action of cholera toxin & other toxins," Indian J. Med. Res., 104:28-37, (1996).	
	C45	Gardiner et al., "Characterisation of Cheddar Cheese Harboring Probiotic Lactobacillus Adjuncts," Int. Dairy Journal, 8(5/6):597, (1998).	
	C46	Gardiner et al., "Cheddar Cheese as a Probiotic Delivery System," Sixth Symposium on Lactic Acid Bacteria, Abstract J28, (1999).	–
	C47	Gardiner et al., "Evaluation of Cheddar Cheese as a Food Carrier for Delivery of a Probiotic Strain to the Gastrointestinal Tract," J. Dairy Sci., 82:1379-1387, (1999).	
	C48	Gardiner et al., "Influence of a Probiotic Adjunct Culture of Enterococcus faecium on the Quality of Cheddar Cheese," J. Agric. Food Chem., 47:4907-4916, (1999).	 "
	C49	Gardiner et al., "Preparation of Spray Dried Powders Harbouring High Levels of Probiotic Lactobacilli," Sixth Symp. on Lactic Acid Bacteria, Abstract J29, (1999).	
V	C50	Gardiner, et al., "Development of a Probiotic Cheddar Cheese Containing Human-Derived Lactobacillus paracasei Strains," Applied and Env. Microbiology, pages 2192-2199, (1998).	

EXAMINER:	V Alon-none	DATE CONSIDERED:	P-10-2006'	1
	V. Afrenor		1 10 000	

V / I

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO)-1449/A and B (n	nodifie	1 PTO/SR/08)	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00
	RMATION I		·	FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753
	EMENT BY		—	APPLICANT: Collins et al.	
Sheet	5	of	10	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova

A	C51	Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor	
1 \ A	1	receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human	
VII		cancer patients," Proc. Natl. Acad. Sci, 87:8781-8784, (1990).	
	C52	Gibson, Glenn, "Dietary modulation of the human gut microflora using prebiotics," Jour. of	
<u> </u>		Nutrition, 80(2):S209-S212, (1998).	
	C53	Gilliland, Stanley, "Health and nutritional benefits from lactic acid bacteria," FEMS Microbiology Reviews, 87:175-188, (1990).	
	C54	Gionchetti et al., "Microflora in the IBD Pathogenesis: Possible Therapeutic Use of Probiotics" Gastroenterology Intl., 11(1):108-110, (1998).	
	C55	Groot, J.A., "Correlation between electrophysiological phenomena and transport of macromole- cules in intestinal epithelium," The Veterinary Quarterly, 20(3):S45-S49, (1998).	
	C56	Halpern et al., "Treatment of Irritable Bowel Syndrome with Lacteol Fort: A Randomized, Double-Blind, Cross-Over Trial," Am Jour. of Gastroenterology, 91(8):1579-1585, (1996).	
	C57	Henderson et al., "Cytokines, homeostasis, networks and disease," Bacteria-Cytokine Interactions in Health and Disease, pages 79-130, (1998).	
	C58	Houde et al., "Treatment of Acute Enteritis with Oral Administration of Short-Term High-Dose Bifidobacteria," Chinese Jour of Microecology, 6(6):47, (1994).	Y
	C59	Huis et al., "Establishing a scientific basis for probiotic R&D," 12:6-8, (1994).	
	C60	Inagaki et al., "Causes of Death in Cancer Patients," Cancer, 33(2):568-573, (1974).	
	C61	Isolauri et al., "Oral Bacteriotherapy for Viral Gastroenteritis," Digestive Diseases and Sciences, 39(12):2595-2600, (1994).	
	C62	Jinggang, Lan, "Immunopotentiating Activity of Bifidobacterium and Its Significance," For. Med. Sci., Clinic Biochem & Med Test, 19(5):231-233, (1998).	Y
	C63	Jong, S.C., "Probiotics for Humans and Animals," ATCC Quarterly Newsletter, 13(1):1-4, (1993).	
	C64	Kagnoff, "Immunology of the Intestinal Tract," Gastroenterology, 105:1275-1280, (1993).	
	C65	Kato et al., "Suppressive Effects of the Oral Administration of Lactobacillus Casei on Type II Collagen-Induced Arthritis in DBA/1 Mice," Life Sciences, 63(8):635-644, (1998).	
	C66	Kawakami et al., "A Group of Bactericidal Factors Conserved by Vertebrates For More Than 300 Million Years," Journal of Immunology, 132(5):2578-2581, (1984).	
	C67	Kim et al., "The Properties of Bifidobacteria Isolated from Korean," Korean Journal of Dairy Science, 20(3):191-204, (1998).	Y-Abstract
	C68	Kim, Hyung, "Characterization of Lactobacilli and Bifidobacteria as applied to Dietary Adjuncts ¹ ," Cultured Dairy Products Journal, pages 6-9, (1988).	
	C69	Klaenhammer, Todd, "Genetics of bacteriocins produced by lactic acid bacteria," FEMS Microbiology Rev., 12:39-86, (1993).	
1	C70	Kühn, et al., "Interleukin-10-Deficient Mice Develop Chronic Enterocolitis," Cell, 75:263-274, (1993).	
M	C71	Kulkarni et al., "Inhibitory Effect of Bifidobacterium longum Cultures on the Azoxymethane- Induced Aberrant Crypt Foci Formation and Fecal Bacterial β-Glucuronidase," Proc. Soc. Experim. Biol. Med., 207:278-283, (1994).	

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

EODA DTO)-1449/A and B (i	modified D	TO/SB/08)	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00	
	RMATION 1			FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753	
	EMENT BY			APPLICANT: Collins et al.		
Cheet		of	10	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova	
Sheet	6	l oi	10	<u></u>		

VA	C72	Lamm et al., "Interaction of antigens and antibodies at mucosal surfaces," Ann Rev Microbiol, 51:311-40, (1997). (Previously cited as Ramos et al.)	
1	C73	Lee et al., "The coming of age of probiotics," Trends in Food Science & Technology," 6:241-245, (1995).	
	C74	Legrand-Defretin et al., "Ion-Pair High-Performance Liquid Chromatography of Bile Salt Conjugates: Application to Pig Bile," LIPIDS, 26(8):578-583, (1991).	
	C75	Leonard, et al., "Regulation of the Inflammatory Response in Animal Models of Multiple Sclerosis by Interleukin-12," Critical Reviews in Immunology, 17:545-553, (1997).	
	C76	Lucey et al., "Developing Fields in Food Biotechnology," Food Science and Technology, 11(4):230-233, (1997).	
	C77	Madsen et al., "Lactobacillus SP prevents development of enterocolitis in interleukin-10 gene deficient mice," Gastroenterology, 112(4):1030, (1997).	
	C78	Malefyt et al., "Interleukin 10 (IL-10) and Viral IL-10 Strongly Reduce Antigen-specific Human T Cell Proliferation by Diminishing the Antigen-presenting Capacity of Monocytes via Downregulation of Class II Major Histrocompatility Complex Expression," J. Exp. Med., 174:915-924, (1991).	
	C79	Mangan et al., "Lipopolysaccharide, Tumor Necrosis Factor-α, and IL-1β Prevent Programmed Cell Death (Apoptosis) in Human Peripheral Blood Monocytes," Journal of Immunology, 146(5):1541-1546, (1991).	
	C80	Marteau et al., "Potential of using lactic acid bacteria for therapy and immunomodulation in man," FEMS Microbiology Reviews, 12:207-220, (1993).	
	C81	Mattila-Sandholm, "Novel Methods for Probiotic Research," Demonstration Project Fair2 CT96-1028, Pages 11-15, (1997).	
	C82	Mattila-Sandholm, et al., "Probiotics: towards demonstrating efficacy," Trends in Food Sci & Tech., 10:393-399, (1999).	
	C83	McBrearty et al., "Probiotic Bifidobacteria and Their Identification Using Molecular Genetic Techniques," Proc. of British Nutritional Foundation, pages 97-107, (2000).	
	C84	McCracken, et al., "Probiotics and the Immune System," Probiotics a Critical Review, pages 85-113, (1999).	
	C85	McFarland, et al., "Pharmaceutical Probiotics for the Treatment of Anaerobic and Other Infections," Anaerobe, 3:73-78 (1997).	
	C86	McGee et al., "A synergistic relationship between TNF-α, IL-1β, and TGF-β1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line," Immunology, 86:6-11, (1995).	
	C87	Medaglini et al., "Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization," Proc. Natl. Acad. Sci, 92:6868-6872, (1995).	
	C88	Mestan et al., "Antiviral effects of recombinant tumour necrosis factor in vitro." Nature. 323:816-819, (1986). (Previously cited as Wong et al.)	
	C89	Morrisey et al., "Election of a Probiotic Strain to Modify Human Gut Flora and a Controlled Trial of Delivery and Efficacy," Ir. Soc. of Gastroenterology, 167(8):7, (1998).	
V#	C90	Murphy et al., "Evaluation and Characterisation of Probiotic Therapy in the CD45RB ^{HI} Transfer Model of Colitis," Gastroenterology, 116(4):A780, (1999). Abstract 3382.	

V. Spenova 8-10-2006		
----------------------	--	--

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00		
		FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753		
		APPLICANT: Collins et al.			
		· ·	·	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova
Sheet	7	of	10		

A	C91	Murphy et al., "Long-term Colonisation with Lactobacillus salivarius subsp. salivarius UCC118: A Probiotic Candidate," Intl. Dairy Journal, 8(5/6):3 pages, (1998).	
	C92	Murphy, et al., "In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract." Microbiol. Ecology in Health and Disease, pages 149-157, (1999).	
	C93	Neutra et al., "M Cells as a Pathway for Antigen Uptake and Processing," Essentials of Mucosal Immunology, 196:29-35, (1996).	
	C94	O'Halloran et al., "Adhesion of Potential Bacteria to Human Epithelial Cell Lines," Intl. Dairy Jour., 8(5/6):3 pages, (1998).	
	C95	Oksanen et al., "Prevention of Travellers' Diarrhoea by Lactobacillus GG," Annual Med., 22(1):53-56, (1990).	
	C96	O'Mahony et al., "Probiotic Bacteria and Pathogenic Bacteria Elicit Differential Cytokine Responses From Dendritic Cells," XP001097379, (2001). Abstract 1625.	
	C97	O'Mahony et al., "Probiotic Bacteria and the Human Immune System," Sixth Symp. on Lactic Acid Bacteria, pages 63-70, (1999).	
	C98	O'Mahony, et al., "Consumption of Probiotic Bacteria Ameliorates Enterocolitis in IL-10 Knock Out Mice," Irish Jour. Med. Sci, 168(5):9, (1999).	
	C99	O'Mahony, et al., "UCC118 Modulates Proinflammatory Cytokine Production In Vitro," Ir. J. Med. Sci., 168(9), (1999).	
	C100	O'Mahony et al., "Probiotic Treatment of Enterocolitis in IL-10 Knock Out Mice." Sixth Symp on Lactic Acid Bacteria. 2 pages. Sept 19/23, (1999). Abstract J30.	
	C101	O'Riordan, et al., "Assessment of Bifidobacterium Strains for Antimicrobial and Exopolysaccharide Production and Evaluation of Pulsed-field Gel Electrophoresis as a Method for Identifying or Discriminating between Bifidobacterial Strains," Intl. Dairy Jour., 8(5/6): 3 pages (1998).	
	C102	O'Riordan et al., "Determination of genetic diversity within the genus Bifidobacterium and estimation of chromosomal size," FEMS Microbiology Letters, 156:259-264, (1997).	
	C103	O'Riordan et al., "Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature," Journal of Applied Microbiology, 85:103-114, (1998).	
	C104	O'Sullivan et al., "Isolation and Selection of Normal Gut Microflora for Use as Prophylactic Probiotic Agents," Irish Society of Gastroenterology, Proc. in Dublin, June 7-8, 1991, pages 419-420.	_
	C105	O'Sullivan et al., "Probiotic Bacteria in the Human Gastro Intestinal Tract (Myth or Reality)," Irish Jour of Med Sci, Proc. of the Irish Soc. of Gastroenterology, Dec. 4-5, 1992, page 273.	
	C106	O'Sullivan et al., "Probiotic bacteria: myth or reality?," Trends in Food Science & Technology, 3:309-314, (1992).	
	C107	O'Sullivan et al., "The Human Gut as a Source of Probiotic Bacteria - Myth or Reality?" Irish Jour. of Med. Sci., page 25, (1993).	
	C108	Panwala, et al., "A Novel Model of Inflammatory Bowel Disease: Mice Deficient for the Multiple Drug Resistance Gene, mdrla, Spontaneously Develop Colitis," Jour. of Immunology, 161:5733-5744, (1998).	
VA	C109	Present et al., "Infliximab for the treatment of fistulas in patients with Crohn's Disease," New Eng. Jour. of Med., 340(18):1398-1405, (1999).	

EXAMINER:	V. Afremora	DATE CONSIDERED: 8-10-2806	
	1,04		

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

000US00

IA	C110	Raychaudhuri et al., "Fully mobilizing host defense: Building better vaccines," Nat. Biotechnol., 16:1025-1031, (1998).	
	C111	Reddy, Bandaru, "Possible Mechanisms by Which Pro- and Prebiotics Influence Colon Carcinogenesis and Tumor Growth ¹ ," Amer. Soc. for Nut. Sci., pages 1478S-1482S, (1999).	-
	C112	Rowland, Ian, "Toxicology of the Colon: Role of the Intestinal Microflora," Human Colonic Bacteria, pages 155-174, (1995).	
	C113	Rumney et al., "Effects of risk-associated human dietary macrocomponents on processes related to carcinogenesis in human-flora-associated (HFA) rats," Carcinogenesis, 14(1):79-84, (1993).	
	C114	Saito et al., "Effects of Soybean Oligosaccharides on the Human Gut Microflora in In vitro Culture," Microbial Ecology in Health & Disease, 5:105-110, (1992).	
	C115	Salminen et al., "Demonstration of safety of probiotics - a review," Int. Jour. of Food Microbiology, 44:93-106, (1998).	
	C116	Sarath et al., "Protease assay methods," Proteolytic Enzymes, Chapter 3, pages 25-55, (1989). (Previously cited as Gauthan et al.)	
	C117	Sarem-Damerdji et al., "In vitro colonization ability of human colon mucosa by exogenous Lactobacillus strains," FEMS Microbiology Letters, 131:133-137, (1995).	
	C118	Savage, D. "Interactions Between the Host and its Microbes," Microbial Ecology of the Gut, pages 277-310, (1977).	
	C119	Scardovi et al., "Genus Bifidobacterium," Bergey's Manual of Systemic Bacteriology," 2:1418-1434, (1986).	
	C120	Schmitt et al., "The Immunostimulatory Function of IL-12 in T-Helper Cell Development and Its Regulation by TGF-β, IFN-γ and IL-4," Chem. Immunology, 68:70-85, (1997).	
	C121	Shanahan et al., "Immunosuppressive agents in inflammatory bowel disease: Current status and future prospects," Can J Gastroenterol, 8(6):383-387, (1994).	
	C122	Shanahan, "Pathogenic mechanisms in inflammatory bowel disease," Gastrointestinal Function, 13:13-28, (1995).	•
	C123	Shanahan et al., "Grand Entry for Listeria," Gastroenterology, 112:1045-1046, (1997).	
	C124	Shanahan, et al., "In vivo Primed Cytotoxic T Cells in Inflammatory Bowel Disease," Inflammatory Bowel Disease, Int'l Congress, pages 101-106, (1988).	
	C125	Shanahan, Fergus, "The Intestinal Immune System," Physiology of the Gastrointestinal Tract, pages 643-684, (1994).	
	C126	Shanahan et al., "Immunosuppressive agents in IBD: current status and future prospects." Inflammatory Bowel Disease, pages 367-373, (1994).	
	C127	Siitonen et al., "Effect of Lactobacillus GG Yoghurt in Prevention of Antibiotic Associated Diarrhoea," Annual Med., 22(1):57-59, (1990).	
	C128	Singh et al., "Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis," Carcinogenesis, 18(4):833-841, (1997).	
	C129	Stallmach et al., "Induction and modulation of gastrointestinal inflammation," Trends Immunology Today, 19(10):438-441, (1998).	
VP	C130	Stanton et al., "Probiotic Cheese," Int. Dairy Journal, 8:491-496, (1998).	

EXAMINER:	V. Afrenous	DATE CONSIDERED: 8-10-2006
	<u>`</u> <u>\</u>	

EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and E	(modified PTO/SR/08)	APPLICATION NO.: 10/783,020	ATTY. DOCKET NO.: A0870.70000US00	
	,	FILING DATE: February 23, 2004	CONFIRMATION NO.: 3753	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: Collins et al.		
Sheet 9	of 10	GROUP ART UNIT: 1651	EXAMINER: Vera Afremova	
Sheet 9	or 10			

	C131	Steidler et al., "Mucosal Delivery of Murine Interleukin-2 (IL-2) and IL-6 by Recombinant Strains	
VA		of Lactococcus lactis Coexpressing Antigen and Cytokine," Infection and Immunity, 66(7):3183-3189, (1998).	
Λ	C132	Tagg et al., "Bacteriocins of Gram-Positive Bacteria," Bacteriolocial Reviews, 40(3):722-756, (1976).	
	C133	Takiguchi et al., "Effects of Fermented-Milk Administration on Fecal Microflora and Putrefactive Metabolites of Healthy Adults and Healthy Elderly Persons," BIFIDUS-FLORES, FRUCTUS ET SEMINA 9, pages 135-140, (1996).	Y-Abstract
	C134	Tancrede, C., "Role of Human Microflora in Health and Disease," Eur. J. Clin. Microbiol. Infect. Dis., 11(11):1012-1015, (1992).	
	C135	Tannock, Gerald, "Effect of Dietary and Environmental Stress on the Gastrointestinal Microbiota," Human Intestinal Microflora in Health & Disease, pages 517-539, (1983).	
	C136	Thornton et al., "Bile tolerance and bile salt hydrolase activity of tactobacilli and bifidobacteria isolated from the human intestine," Gastroenterology, 108(4):A928, (1995).	
	C137	Thornton et al., "Human Intestinal Probiotic Bacteria: Production of Antimicrobial Factors," Irish Jour of Med. Sci., 2 pages, (1993).	
	C138	Thornton et al., "Towards an Understanding of the Survival Mechanisms Employed by the Health Promoting Commensal Flora of the Human Small Intestine," Irish Jour. of Med. Sci., Page 603, (1994).	
	C139	Thornton et al., "Determination of stringent criteria essential to the survival/growth/colonisation of probiotic human intestinal tract bacteria," Book of Abstracts Eur. Comm. Biotech and Fair Programmes, page 28, (1995). (Previously cited as Collins et al.)	
	C140	Thornton et al., "The Production of a Novel Antimicrobial Substance by Human Intestinal Microflora," Irish Jour. of Med Sci, pages 603-604, (1994).	
	C141	Thornton, et al., "Bile Acid Tolerance and Deconjugating Activity of Lactobility," Irish Jour. of Med. Sci., 2 pages, (1994).	
	C142	Toba et al., "Potential of Lactobacillus gasseri isolated from infact faeces to produce bacteriocin," Letters in Applied Microbiology, 12:228-231, (1991).	
	C143	van Eys, Jan, "Nutrition and Neoplasia," Nutrition Reviews, 40(12):353-359, (1982).	
	C144	Vaughan et al., "Identification and characterization of helveticin V-1829, a bacteriocin produced by Lactobacillus helveticus 1829," Journal of Applied Bacteriology, 73:299-308, (1992).	
	C145	Vaughan et al., "Isolation from food sources, of lactic acid bacteria that produced antimicrobials," Journal of Applied Bacteriology, 76:118-123, (1994).	
	C146	Veld et al., "Selection criteria for probiotic micro-organisms," International Congress and Symposium Series 219, pages 27-36 (1996).	
	C147	Wahl et al., "IFN-γ Inhibits Inflammatory Cell Recruitment and the Evolution of Bacterial Cell Wall-Induced Arthritis," Journal of Immunology, 146(1):95-100, (1991).	
V	C148	Walker, Richard, "New strategies for using mucosal vaccination to achieve more effective immunization," Vaccine, 12:387-400, (1994).	
VA	C149	Wu, et al., "Transfection of Ovarian Cancer Cells with Tumor Necrosis Factor-α (TNF-α) Antisense mRNA Abolishes the Proliferative Response to Interleukin-1 (IL-1) but Not TNF-α," Gynecologic Oncology, 53:59-63, (1994). (Formerly cited as Meeker et al.)	

		<u>:.</u>	
EXAMINER:	V. Afremore	DATE CONSIDERED:	8-10-2006

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1440/A and P (modified PTO/SP/08)			APPLICATION NO.: 10/783	,020	ATTY. DOCKE	ET NO.: A0870.70000US00	
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: February 23, 2004		CONFIRMATION NO.: 3753			
		APPLICANT: Collins	et al.				
				CROUD ART INIT. 1651		EXAMINER:	Vera Afremova
Sheet	10	of	10	GROUP ART UNIT: 1651		EAAWIINEK:	veia Alfelliova

CI	Yang et al., "Genetics of Inflammatory Bowel Disease," Chapter 3, pages 32-64, (1994).	
A CI	Cong et al., "CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease," J Exp Med, 187(6):855-64, (1998).	

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: V. Afrensk DATE CONSIDERED: 8-10-2006

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (Modified)

JACOBSON HOLMAN PLLC

400 SEVENTH STREET, N.W.

WASHINGTON, D.C. 20004-2201

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.: P66879US3 GROUP ART UNIT: __ 1651 SERIAL NO.: FILING DATE: 10/783020 February 23, 2004 July 27. APPLICANT(S): COLLINS TODAY'S DATE: ------U.S. PATENT DOCUMENTS DOCUMENT SUB-*EXAMINER FILING DATE NUMBER DATE NAME CLASS CLASS INITIAL If Appropriate) AA 4435389 03/06/84 424 Mutai et al 181 AB 5032399 07/16/91 Gorbach et al-93 424 AC 5443826 08/22/95 Borody---424 93 AD 07/13/99 Euchansky et al 426 61 5922375 ΑE 6132710 10/17/00 Panigraphi et al 424 93 AF 6645530 424 543 Borody FOREIGN PATENT DOCUMENTS DOCUMENT SUB-TRANSLATION DATE COUNTRY CLASS NUMBER CLASS YES) AG 0384319B1 08/29/90 Europe AΗ 0508701B1 10/14/92 Europe ΑI 0904784A1 03/31/99 Europe 05/21/03 AJ 1312667A1 Europe AK 1503094 03/08/78 Great Britain AL2091075 09/27/97 Russia Abstract AM 04/20/98 2109054 Russia Abstract AN W089/05849 06/29/89 WIPO 02/22/90 AO WO90/01335 WIPO AP W090/09398 08/23/90 WIPO WO*97/*35596 A0 10/02/97 WIPO **WO98/00035** AR 01/08/98 WIPO ΆŚ WO99/51631 10/14/99 WIPO AΤ W099/62348 12/09/99 WIPO 05/31/01 WO01/37865 AU WIPO ΑV 9-241173 09/16/97 <u>Japan</u> Abstract EXAMINER DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

JACOBSON HOLMAN PLLC 400 SEVENTH STREET, N.W.

WASHINGTON, D.C. 20004-2201

ATTY.	DOCKEL	MO::	P66879US3	_ GROUP ART U	NIT:
SERIAL	. NO.:		10/783020	_ FILING DATE	: <u>February 23, 2004</u>
APPLIC	ANT(S)	: .	COLLINS	TODAY'S DAT	E: <u>July 27, 2004</u>
****	*****	****	******	******	*******
	OTHER	ART (1	Including Author, I	itle, Date, Perti	inent Pages, Etc.)
in					
VΠ	AW	<u>Kühn</u>	et al, CELL, Vol 7	5, 10/22/93, pgs.	263-274, Aublicate
\mathcal{N}		<u>Inter</u>	<u>leukin-10-Deficien</u>	t Mice Develop Ch	ronic Enterocolitis
	AX	<u>Marte</u>	<u>au et al, FEMS MIC</u>	ROBIOLOGY REVS 12	, 1993, pgs. 207-220, 1.10
		<u>Poten</u>	tial of using lact	ic acid bacteria	for therapy and dupt
	AY	Rumne	y et al, CARCINOGE	NESIS, Vol 14, No	1, 1993, pgs. 79-84,
- 1					macrocomponents on
\perp	ΑZ	<u>0'Sul</u>	<u>livan et al, IRISH</u>	JOUR OF MED SCI,	PROC OF THE IRISH SOC
		OF GA	STROENTEROLOGY, De	c 4-5, 192, Probi	otic Bacteria in the
<u> </u>	AA1_	<u>Adaeh</u>	i, THE LACTIC ACID	BACTERIA, Vol'1,	1992, pgs. 233-261, duffic
-		<u>Lacti</u>	<u>c Acid Bacteria an</u>	d the Control of	Tumours
4	AB1	<u>Chauv</u>	<u>iere et al, JOURNA</u>	<u>L OF GENERAL MICR</u>	OBIOLOGY 138, 1992, pgs.
		<u> 1689-</u>	1696, Adhesion of	numan/Lactobacill	lus acidophilus strain
	AC1	<u> O'Sul</u>	<u>livan et al, TREND</u>	S IN FOOD SCIENCE	& TECH, Vol 31, Dec.
ł				•	myth or reality
	AD1				S, Vol 11, No 11, Nov.
		<u>1992,</u>	<u>pgs. 1012-1015, R</u>	ole of Human Micr	oflora in Health and
+	AE1				73, 1992, pgs. 299-308,
			<i>*</i>		<u>elveticin V-1829, a</u>
	AF1				1991, pgs. 915-924,
			/		trongly Reduce
+	AG1				EROLOGY, Proc in Dublin
					nd Selection of Normal
+	AH1	_			6, No 5, pgs. 1541-1546,
					ecrosis Factor- α and
₩	AÍ1				, 1991, pgs. 228-231,
À/	<i>-</i>				ted from infant
<u> </u>	AJ1	Wahl		-	No 1, pgs. 95-100, Jan
	Luk	$\int \frac{1}{4} \frac{169}{12}$	91, IFN-y Inhibits	Inflammatory Cel	l Recruitment and the
	Im	Minn	Л'		
EXAMINER	~~ ~/	11/2-		DATE CONSIDERED	2 10 - 7ho 1
	<u> </u>	Mh	muv		0-10-1006
			·		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.: <u>P66879US3</u> GROUP ART UNIT: <u>1651</u>
SERIA	L NO.:	10/783020 FILING DATE: February 23, 2004
APPLI	CANT(S)	
****	****	. * * * * * * * * * * * * * * * * * * *
	OTHER	ART (Including Author, Title, Date, Pertinent Pages, Etc.)
. Λα		
VH	AK1	Cicco et al, BLOOD, Vol 75, No 10, 1990, pgs. 2049-2052,
<u> </u>		Inducible Production of Interleukin-6 by Human
/1	AL1	Donnelly et al, JOUR OF IMMUNOLOGY, Vol 145, No 2, Jul 15, 1990,
		pgs. 569-575, Differential Regulation of IL-1 Production in
	AM1	Gatanaga et al, PROC NATL ACAD SCI, Vol 87, pgs. 8781-8784, Nov.
\top		1990, Purification and characterization of an inhibitor
- 1	AN1	Gilliland, FEMS MICROBIOLOY REV 87, pqs. 175-188, 1990, Health
\top		and nutritional benefits from lactic acid bacteria
- 1	A01	Fuller, JOUR OF APPL BACTERIOLOGY 66, 1989, pqs. 365-378,
\top		Probiotics in man and animals
	AP1	Dinarello et al, REV OF INFECTIOUS DIS, Vol 10, No 1, Jan/Feb
		1988, pgs. 168-189, New Concepts on the Pathogenesis of Fever
	AQ1	Ferrante et al, INT ARCHS ALLERGY APPL IMMUN 86, 1988, pqs. 82-
	~	91, Effects of Tumour Necrosis Factor Alpha and Interleukin-1
- 1	AR1	Kim, CULTURED DAIRY PROD JOUR, Aug 1988, pgs. 6-9, Character-
T		ization of Lactobacilki and Bifidobacteria as applied to
	AS1	Shanahan et al, INFLAMMATORY BOWEL DISEASEINTL CONGRESS, 1988
		pgs. 101-106, In vivo primed cytotoxic T cells in inflammatory
	AT1	Bachwich et al BIOCHEM AND BIOPHYS RES COMMUN, Vol 136, No 1,
		Apr 14, 1986 pgs. 94-101, Tumor Necrosis Factor Stimulates
	AU1	Wong et al, NATURE, Vol 323, Oct 1986, pgs. 816-819, Antiviral
		effects of recombinant tumour necrosis factor in vitro
	AV1	Anand et al, CULT DAIRY PROD 2, 1985, pgs. 21 and 23, Anti-
		bacterial Activity Associated with Bifidobacterium bifidum - II
1/-	AW1	Kawakami et al, JOUR OF IMMUNOLOGY, Vol 132, No 5, May 1984, A
X .		Group of Bactericidal Factors Conserved by Vertebrates for
JH_	AX1	Tannock, HUMAN INTESTINAL MICROFLORA IN HEALTH & DISEASE, 1983,
		pgs. 517-539, Effect of Dietary and Environmental Stress on
	116	Mirales
	- M	
EXAMINER		DATE CONSIDERED 8-10-2006
		V 39 (F V -

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.: _	P66879US3	- 	GROUP ART	UNIT:	1651	<u> </u>
SERIAL	NO.:	_	10/783020		FILING DA	ATE:	February	23, 2004
APPLIC	ANT(S):		COLLINS		TODAY'S I	DATE: _	July 27,	2004
*****	*****	*****	******	*****	*****	*****	******	*****
	OTHER	ART (I	ncluding Aut	thor, Titl	e, Date, Pe	rtinent	Pages, E	:c.) /
· M -			_					
VH	AY1	Savage	e, IN: MICRO	BIAL ECOL	OGY OF THE C	GUT, 19	77, pqs. 2	:77-3/10,
$\overline{\Lambda}$			action betwe	_				
	AZ1	Crabbe	e et al, INT	ARCH ALL	ERGY 34, 196	spq ,83	. 362-375,	The
			l Microbial	-				
	AA2		ony et al, F					
			63-70, Probi				/	
İ	AB2		arty et al,					
			97-107, Prob					
	AC2		et al, TREND					
T			ion studies					
	AD2		ns et al, GA		· / /			
			trolled Tria					
	AE2		ns et al, GA		/			
T			otics and Ma					
	AF2	Darve	au, NATURE B	IOTECHNOL	OGY, Vol 17,	Jan 1	999, pq. 1	.9,
T			tion, inflam	/				
	AG2	Dunne	et al, GAST	ROENTEROL	OGY, Vol 116	5, No 4	, Apr 1999	, 2 pqs.
			elial Adhesi					
	AH2		ony et al, I					
			obiotic Bact					
	AI2	O'Mah	ony et al, S	SIXTH SYMP	ON LACTIC A	CID BA	CTERIA,	Sept 19/
		23,/19	999, 2 pqs.,	Probioti	c Treatment	of Ente	erocolitis	in
	AJ2	Gardin	ner et al, S	SIXTH SYMP	ON LACTIC A	ACID BAC	CTERIA	Sept 19/
ľ		<u>23, 19</u>	999, 2 pgs.,	Cheddar	Cheese as a	Probiot	tic Delive	ry System
	AK2	Gardin	ner et al, S	SIXTH SYMP	ON LACTIC A	CID BAC	CERTIA	Sept 19/
		23, 19	999, 2 pgs.,	Preparat	ion of Spray	/ Dried	Powders	•
<u> </u>	AL2	O'Maho	ony et al, I	RISH JOUR	OF MED SCI,	Nov 2	6/27, 1999	UCC118
		Modula	ates Proinfl	ammatory	<u>Cytokine Pro</u>	duction	<u>n in Vitro</u>	,
	n	$0 M \Pi M$	reader					
	· · · · · ·	- 1 w					CA CAME	/
EXAMINER	V.	Hoe	mu		DATE CONSIDERED	8-1	(U - ZUV	6

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.: P	66879US3	GR	OUP ART UNIT	r: <u>165</u> 1	<u>l</u>
SERIAL	NO.:	<u> </u>	0/783020	FI	LING DATE: _	February	23, 2004
APPLIC	CANT(S):		OLLINS	TO	DAY'S DATE:	<u>July 27,</u>	2004
*****	*****	*****	*****	*****	******	*****	*****
	OTHER	ART (Incl	uding Author,	Title, Da	te, Pertine	nt Pages, E	tc.)
IM-							
VIT	AM2	Gardiner	et al, J DAIR	Y SCI Vol	82, No 7, 1	1999, pqs. 3	1379-1387,
		Evaluati	on of Cheddar	Cheese as	a Food Carr	rier for De	very
/	AN2		et al, J AGRI				
			e of a Probiot				
	AO2		Sandholm et al				
			-399, Probioti				
	AP2		n et al, PROBI				
			cs and the Imm				
	AQ2		t al, GASTROEN			4, 1999, 2	2 pas.,
	-		on and Charact				
	AR2		t al, MICROBIA		,		
			In vivo asses				
1	AS2		et al, NEW ENG				
			s. 1398-1405,	/			-
	AT2		MER SOC FOR MU				
			ms by Which Pr				
ļ	AU2		an et al, INTL				
			of Potential				
	AV2		al, INTL DAIR			-	
		-	and Characte				
-	AW2		s et al, JOUR				
1			6-1643, Antibi				
	AX2	/	s et al, Jour				
	/	/	Development a				
	AX2		et al, INT DAI			·	
V.			otic Strains f				
<u> </u>	AZ2		et al, APPL A				Jo 6, 1998,
			2-2199, Develo		-		
	di	Mosca	Les				
EXAMINER	, 1	- 1	,	DATE CO	DNSIDERED	0100	400 /
	V	# De	mu			8-10-2	000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.: <u>P66879US3</u>	GROUP ART UNIT: 1651
SERIAL	NO.:	10/783020	FILING DATE: <u>February 23, 2004</u>
APPLIC	CANT(S):	:COLLINS	TODAY'S DATE: July 27, 2004
		 	
*****	*****	*******	*********
	OTHER	ART (Including Author, Tit	tle, Date, Pertinent Pages, Etc.)
۸۸		_	
V#,	AA3	Gardiner et al, INTL DAIR	Y JOUR, Vol 8, No 5/6, 1998, 3 pgs
- V		Characterisation of Chedd	ar Cheese Harboring Probiotic
	AB3	Kato et al, LIFE SCIENCES	, Vol 63, No 8, 1998, pqs. 635/644,
			e Oral Administration of
	AC3		F MED SCI, Vol 167, Supp No 8, 1998,
		2 pgs., Election of a Pro	biotic Strain to Modify
	AD3	Murphy et al, INTL DAIRY	JOUR, Vol 8, No 5/6, 1998, Long-term
•		Colonisation with Lactoba	cillus salivarius subsp. salivarius
	AE3	Feency et al, INTL DAIRY	JOUR, Vol 8, No/5/6, 1998, Lack of
		Specific Systemic Immune	Response on Oral Consumption of
	AF3	O'Riordan et al, INTL DAI	RY JOUR, VØ1 8, No 5/6, 1998, Asess-
		ment of Bifidobacterium S	strains for antimicrobial and
	AG3	Collins, FUNCTIONAL FOOD	RESEARCH IN EUROPE, Oct 1/2, 1998, pq.
- 1		124, Probiotics and Infla	mmatory Bowel Disease: Animal Models
	AH3	Collins et al, FUNCTIONAL	FOOD RESEARCH IN EUROPE, Oct 1/2, 1998
		pgs. 40-41, Demonstration	of Probiotic Function in a Double
	AI3	O'Riordan et al, JOUR OF	APPL MICROBIOLOGY, Vol 85, 1998, pgs.
		103-114, Evaluation of bi	fidobacteria for the production of
	AJ3	Panwala et al, JOUR OF IM	MUNOLOGY, Vol 161, 1998, pgs. 5733-
		5744, A Novel Model of In	flammatory Bowel Disease: Mice
	AK3	Raychaudhuri et al, NAT B	IOTECHNOL, Vol 16, 1998, pgs. 1025-1031
1		Fully mobilizing host def	ense: Building better vaccines
	AL3	Salminer et al, INTL JOUR	OF FOOD MICROBIOLOGY 44, 1998, pgs.
. //		93-106, Demonstration of	safety of probiotics - a review
	AM3	, - · · · · · · · · · · · · · · · · · ·	OGY 115, 1998, pgs. 1595-1600, Genes,
M			gredients for Inflammatory Bowel
V # -	AN3		MMUNOLOGY TODAY, Vol 19, No 10, Oct.
		1998, pgs. 438-441, Induc	tion and modulation of
		Mullscases	
PVANTAMA		h 12	200
EXAMINER	V	. Ispenan	DATE CONSIDERED 8-10-2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

• •

JACOBSON HOLMAN PLLC

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.:	P66879US3	_ GROUP ART UNIT	:1651
SERIA	L NO.:		10/783020	_ FILING DATE: _	February 23, 2004
APPLI	CANT(S):	:	COLLINS	TODAY'S DATE:	July 27, 2004
****	*****	****	******	*****	******
	OTHER	ART ()	Including Author, I	Title, Date, Pertinen	t Pages, Etc.)
M					
VIII	AO3	Stant	on et al. INT DAIR	Y JOUR 8, 1998, pqs.	491-496. Probiotic
<u> </u>		Chees			
M	AP3			CLINIC BIOCHEM & MED	TEST Vol 19(5).
				unopotentiating Activ	
- 1	AQ3				1. 11, Supp 1, 1998,
		`		ra in the IBD Pathoger	
- 1	AR3			, , , , , , , , , , , , , , , , , , , ,	1998, pqs. 3183-3189
					L-2) and IL-6 by
- 1	AS3				OL 18, 1997, pqs. 555
				f human inflammatory	
	AT3				LOGY 35, 1997, pqs.
					identification of
	AU3				62, Dec 1997, pqs.
					cytogenes in tumor
	AV3				7, pgs. 341-373,
				of the Pseudomonas	
	AW3				GY 17, 1997, pgs. 545
\top					se in Animal Models
	AX3			TECH TODAY 11(4), 19	
			oping Fields in Fo		<u> </u>
1	AY3		7 -	BE 3, 1997, pgs. 73-	78. Pharmaceutical
				tment of Anaerobic ar	
	AZ3				, 1997, pqs. 259-264,
		/		c diversity within th	
7	AA4			UNOL 68, 1997, pgs.	
M				IL-12 in T-Helper Ce	
VH_	AB4		— -	NTEROLOGY 112, 1997,	
	١.	Grand	Entry for Listeri	a	
/	all l	X CO	As.		_ :
	1 - or br	,)		
EXAMINER	V	\mathcal{A}	Remove	DATE CONSIDERED	~ 10 ~ W0 b
	<u>V</u>	<u> </u>	1 100		

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

ATTY.	DOCKET	NO.: <u>P66879US3</u>	GROUP ART UNIT:	1651
SERIA	L NO.:	10/783020	FILING DATE:	February 23, 2004
APPLI	CANT(S):	: <u>COLLINS</u>	TODAY'S DATE: _	July 27, 2004
****	********	**************************************		*****************
	OTHER	ART (Including Author, 110	ie, bate, reftiment	t Pages, Etc.,
$\frac{\bigvee \mathcal{H}}{\Delta}$	AC4	Mattila-Sandholm, DEMONST		
化	AD4	Collins, DEMONSTRATION FA		
		Selection and safety crite		_
\perp	AE4	Arihara et al, LTRS IN AP Salivacin 140, a novel ba	PL MICROBIOLOGY 22,	1996, pgs. 420-424,
ļ	AF4	Collins et al, INT CONG &	,	
\top		Probiotic bacteria - inte		
	AG4	Daly et al, ANTONIE VAN LI		
- 1		technology of lactic acid	bacteria with spec	ial reference to
	AH4	Neutra et al, ESSENTIALS (
		M Cells as a Pathway for		
	AI4	Collins, BOOK OF ABSTRACTS		
1		Oct 1995, pg. L2, Selection		
	AJ4	Collins, BOOK OF ABSTRACTS		
- 1	3774	Oct 1995, pg. pA-3, Determ		
	AK4	Lee et al, TRENDS IN FOOD		1995, pgs. 241-245,
1	7 T 1	The coming of age of prob		77. 1005
	AL4	Medaglini et al, PROC NATI -6872, Mucosal and system:		
	AM4	Sarem-Damerdji et al, FEMS		
		137 In vitro colonization		
	AN4	Shanahan, EXCERPTA MEDICA		
T^{-}		mechanisms in inflammatory		
$-\!$	A04	Thornton et al, GASTROENTE		-A928 Suppl. S, Apr.
r sk		1995, Bile tolerance and h	oile salt hydrolase	activity of
VI	AP4	Brink et al, JOUR OF APPL		
		Antimicrobial activity of	lactobacilll: prel	iminary
		L. Disemora		
EXAMINER	\	J. Afremor	DATE CONSIDERED	-10-2006
				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

ATTY. DOCKET NO.: P66879US3

JACOBSON HOLMAN PLLC

400 SEVENTH STREET, N.W.

WASHINGTON, D.C. 20004-2201

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

GROUP ART UNIT: _____1651

SERIAL NO.:	10/783020	FILING DATE:	<u>February 23, 2004</u>
APPLICANT(S)	: <u>COLLINS</u>	TODAY'S DATE	: July 27, 2004
*****	********	******	·********
, on OTHER	ART (Including Author, Tit)	le, Date, Pertin	ent Pages, Etc.)
VIII AQ4	Thornton et al, IRISH JOUR		
	Bile acid tolerance and de		
/\\ AR4	Thornton et al, IRISH JOUR		
	604. The production of a n		
AS4	Thornton et al, IRISH JOUR		
	Towards an understanding o		
AT4	Houde et al, CHINESE JOUR		
	1994, Treatment of Acute E		,
AU4	Shanahan et al, INFLAMMATO		· · · · · · · · · · · · · · · · · · ·
	Immunosuppressive agents i		
AV4	Shanahan et al, CAN J GAST		/
	pqs. 383-387, Immunosuppre	/	
AW4	Shanahan, PHYSIOLOGY OF TH		
	643-684, The Intestinal Im		and Heact, 1994, pgs.
AX4	Huis et al, Establishing a		is for Probiotic PCD
	Vol 12, pqs. 6-8, Jan. 199		is for Frobiotic Rab,
AY4	Walker, VACCINE, Vol 12, 1		New strategies for
	using mucosal vaccination/		
AZ4	Vaughan et al, JOUR OF APP		
	-123, Isolation from food		
AA5	Jong et al, ATCC OVARTERLY		
	Probiotics for Humans and		1 13, NO 1, 1993,
AB5	Thornton et al IRISH JOUR		, 28/29 1992 2 pgs
	Human intestinal probiotic		
AC5	O'Sullivan et al, IRISH JO		
	pq. 25, The human gut as a		
AD5	Kagnoff, GASTROENTEROL 105		
	of the intestinal tract	(3), 1333, pqs.	1275-1280, IllillianOlogy
AE5	Klaenhammer, FEMS MICROBIO	IOGV PEV 12 190	23 pgs 39-86 Cenetic
	of bacteriocins produced b		
APS	O'Mahony et al, XP-0010973		
	Pathogenic Bacteria Elicit		
	^ .	DILLECT CHICAGE CY	r
XAMINER	Hoemen	DATE CONSIDERED	8-10-7166
V	. 4/4/01/01/0		C) TO DATE

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)